News coverage about Qiagen (NYSE:QGEN) has trended somewhat positive on Thursday, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Qiagen earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.2228105713643 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Qiagen (NYSE:QGEN) opened at $32.31 on Thursday. Qiagen has a fifty-two week low of $27.74 and a fifty-two week high of $36.34. The stock has a market cap of $7,390.22, a PE ratio of 25.50, a price-to-earnings-growth ratio of 1.96 and a beta of 1.03. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.07 and a quick ratio of 4.78.
TRADEMARK VIOLATION WARNING: “Qiagen (QGEN) Given Coverage Optimism Rating of 0.15” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2018/02/08/qiagen-qgen-given-coverage-optimism-rating-of-0-15.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.